Showing results (1131-1140 of 6,501) with videos related to

Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|July 4, 2021
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumorsHamid Khodayari, Saeed Khodayari, Elmira Ebrahimi, et al.
Cancer Immunology, Immunotherapy : CII|July 11, 2021
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibodyRama Krishna Narla, Hardik Modi, Daniel Bauer, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALLYue Tan, Jing Pan, Biping Deng, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics valuesA Reum Kim, Kyu Sung Choi, Min-Sung Kim, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscapeSeung Geun Song, Sehui Kim, Jaemoon Koh, et al.
Cancer Immunology, Immunotherapy : CII|June 26, 2021
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cellsChristiane Braun, Sebastian Schlaweck, Solveig Nora Daecke, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2020
Adenosine-producing regulatory B cells in head and neck cancerSandra S Jeske, Matthias Brand, Andreas Ziebart, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2020
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapiesCsaba Kerepesi, Tibor Bakacs, Ralph W Moss, et al.
Cancer Immunology, Immunotherapy : CII|March 4, 2020
Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancerMasaki Shiota, Naohiro Fujimoto, Yoshiaki Yamamoto, et al.
Cancer Immunology, Immunotherapy : CII|April 5, 2020
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockadeIsobel S Okoye, Lai Xu, John Walker, et al.
Pageof 651